

# Pal Miheller

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5934959/pal-miheller-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55  
papers

1,495  
citations

24  
h-index

37  
g-index

73  
ext. papers

1,696  
ext. citations

2.7  
avg, IF

3.85  
L-index

#	Paper	IF	Citations
55	Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals - Prospective observational cohort study.. <i>Dermatologic Therapy</i> , <b>2022</b> , e15408	2.2	1
54	Anti-Interleukin-17 Therapy of Severe Psoriatic Patients Results in an Improvement of Serum Lipid and Inflammatory Parameters Levels, but Has No Effect on Body Composition Parameters. <i>Life</i> , <b>2021</b> , 11,	3	2
53	Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
52	Letter: suicide risk among adult inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1213-1214	6.1	1
51	Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 205-213	5.4	4
50	Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2020</b> , 5, 1063-1075	18.8	11
49	Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 1181-1187	5.4	5
48	Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 885-890	4.1	20
47	Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?. <i>Journal of Crohns and Colitis</i> , <b>2017</b> , 11, 697-705	1.5	25
46	Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1908-1915	4.5	36
45	Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2017</b> , 109, 26-32 <sup>0.9</sup>		14
44	Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice. <i>Journal of Crohns and Colitis</i> , <b>2016</b> , 10, 26-30	1.5	28
43	Antibody and cell-mediated immune response to whole virion and split virion influenza vaccine in patients with inflammatory bowel disease on maintenance immunosuppressive and biological therapy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2015</b> , 50, 174-81	2.4	6
42	Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133836	3.7	36
41	Prevalence of inflammatory bowel disease among coeliac disease patients in a Hungarian coeliac centre. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 141	3	41
40	Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. <i>Digestive Diseases</i> , <b>2015</b> , 33, 52-7	3.2	52
39	Have biologics changed the natural history of Crohn's disease?. <i>Digestive Diseases</i> , <b>2014</b> , 32, 351-9	3.2	35

38	Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. <i>PLoS ONE</i> , <b>2014</b> , 9, e115415	3.7	70
37	Probiotics in the management of Crohn's disease and ulcerative colitis. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 4556-60	3.3	6
36	Coeliac disease in a 15-year period of observation (1997 and 2011) in a Hungarian referral centre. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 461-7	3.9	9
35	Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2013</b> , 48, 1394-8	2.4	41
34	Recommendations for identifying Crohn's disease patients with poor prognosis. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 65-75; quiz 76	5.1	18
33	Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice?. <i>Expert Review of Clinical Immunology</i> , <b>2013</b> , 9, 871-82	5.1	
32	Does dermatitis herpetiformis result in bone loss as coeliac disease does? A cross sectional study. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2013</b> , 105, 187-93	0.9	5
31	Manipulating bone disease in inflammatory bowel disease patients. <i>Annals of Gastroenterology</i> , <b>2013</b> , 26, 296-303	2.2	2
30	Methotrexate: should we start using it in clinical practice?. <i>Current Drug Targets</i> , <b>2013</b> , 14, 1480-9	3	2
29	The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis. <i>Pathology and Oncology Research</i> , <b>2012</b> , 18, 85-91	2.6	38
28	Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. <i>Expert Opinion on Biological Therapy</i> , <b>2012</b> , 12, 179-92	5.4	23
27	Endoscopic solutions for stricturing Crohn's disease. <i>Interventional Medicine &amp; Applied Science</i> , <b>2012</b> , 4, 74-77	0.7	
26	Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 1298-303	2.4	13
25	The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases. <i>Digestive Diseases</i> , <b>2012</b> , 30, 289-95	3.2	66
24	Effect of proton-pump inhibitor therapy on serum chromogranin a level. <i>Digestion</i> , <b>2011</b> , 84, 22-8	3.6	53
23	Nutritional influences in selected gastrointestinal diseases. <i>Digestive Diseases</i> , <b>2011</b> , 29, 154-65	3.2	3
22	Low bone mass in microscopic colitis. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 58	3	8
21	Thiopurines in Crohn's disease, is there something new?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2010</b> , 6, 1505-14	5.5	7

20	Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. <i>Journal of Crohns and Colitis</i> , <b>2010</b> , 4, 283-90	1.5	36
19	Pregnancy outcome in patients with inflammatory bowel disease according to the activity of the disease and the medical treatment: a case-control study. <i>Scandinavian Journal of Gastroenterology</i> , <b>2010</b> , 45, 1302-6	2.4	59
18	Bone Homeostasis in Intestinal Disorders. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , <b>2010</b> , 8, 140-148		
17	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 5233-40	5.6	15
16	Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 365-74	4.5	51
15	Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1656-62	4.5	100
14	IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn's disease in Hungarian patients. <i>International Journal of Colorectal Disease</i> , <b>2009</b> , 24, 503-7	3	10
13	The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients. <i>Digestive Diseases and Sciences</i> , <b>2009</b> , 54, 351-9	4	13
12	Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study. <i>BMC Gastroenterology</i> , <b>2009</b> , 9, 66	3	23
11	New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 665-81	0.7	119
10	Chemoprevention of colorectal cancer: feasibility in everyday practice?. <i>European Journal of Cancer Prevention</i> , <b>2008</b> , 17, 502-14	2	16
9	Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. <i>Disease Markers</i> , <b>2008</b> , 25, 1-16	3.2	76
8	Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. <i>Pathology and Oncology Research</i> , <b>2008</b> , 14, 31-7	2.6	33
7	Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 984-92	4.5	59
6	Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 1379-84	4.5	47
5	Carcinogenesis in inflammatory bowel disease. <i>Digestive Diseases</i> , <b>2007</b> , 25, 267-9	3.2	50
4	Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. <i>British Journal of Nutrition</i> , <b>2007</b> , 98, 345-50	3.6	24
3	Repeated infliximab therapy after serum sickness-like reaction in Crohn's disease. <i>Journal of Emergency Medicine</i> , <b>2007</b> , 32, 209-10; author reply 210	1.5	8

2 Automated virtual microscopy of gastric biopsies. *Cytometry Part B - Clinical Cytometry*, **2006**, 70, 423-313,4 6

1 Infliximab therapy improves the bone metabolism in fistulizing Crohn's disease. *Digestive Diseases*, **2006**, 24, 201-6 3,2 24